DIABETIC · AUTOIMMUNE · CIPN · CIDP · IDIOPATHIC · ALL TYPES EVALUATED
A physician-led programme targeting the inflammatory and regenerative mechanisms of peripheral nerve damage — designed to reduce neuropathic pain, restore sensation and improve functional independence.
Request Medical ConsultationAbout the Condition
Peripheral neuropathy is damage to the peripheral nervous system — the network of nerves outside the brain and spinal cord that transmits signals between the CNS and the rest of the body. When these nerves are damaged, communication between the brain and muscles, skin and organs is disrupted.
Symptoms typically include burning, stabbing or shooting pain (often worse at night), numbness and tingling in the feet, legs and hands, loss of tactile and temperature sensation, muscle weakness and balance problems. In some forms, autonomic dysfunction affects digestion, blood pressure and bladder control.
Peripheral neuropathy has many causes and affects millions of people worldwide. Standard treatment focuses primarily on pain management — anticonvulsants, antidepressants and analgesics — which address symptoms but do not repair the underlying nerve damage. Our programme targets the biological mechanisms of nerve injury itself.
Diabetic Peripheral Neuropathy (DPN)
The most common cause of peripheral neuropathy worldwide, affecting approximately 50% of people with diabetes. Chronic hyperglycaemia damages peripheral nerves through a combination of direct metabolic toxicity, inflammation and vascular insufficiency. DPN is among the most responsive subtypes to MSC-based therapy in our clinical experience.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A frequent and debilitating side effect of cancer treatment, caused by the neurotoxic effects of platinum-based agents, taxanes, vinca alkaloids and other chemotherapy drugs. CIPN can persist for months or years after completing cancer treatment and has very limited conventional treatment options.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A progressive autoimmune demyelinating neuropathy in which the immune system attacks the myelin sheath of peripheral nerves. CIDP causes progressive weakness, numbness and impaired motor function. Standard treatment includes immunoglobulins and corticosteroids, but many patients experience incomplete response or significant side effects.
Idiopathic and Small Fiber Neuropathy
Nerve damage without an identified cause (idiopathic) or affecting unmyelinated pain and autonomic fibres (small fiber neuropathy). These forms are often underdiagnosed and undertreated. Patients frequently describe burning pain, temperature sensitivity and autonomic symptoms that standard nerve conduction studies may not detect.
Charcot–Marie–Tooth Disease (CMT)
Hereditary motor and sensory neuropathy causing progressive muscle weakness and atrophy, primarily in the feet, legs, hands and forearms. CMT is the most common inherited neurological disorder. While the genetic basis cannot be altered, our programme targets the inflammatory and metabolic mechanisms that influence the rate of functional decline.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment evaluating neuropathy subtype, nerve conduction data, symptom pattern and medical history.
Our programme targets the biological mechanisms of nerve damage — inflammation, axonal degeneration and impaired nerve regeneration. It is designed to go beyond symptomatic pain management to support actual nerve fibre repair and functional recovery.
Clinical Outcomes
Based on 184 peripheral neuropathy patients (diabetic, autoimmune and idiopathic subtypes) treated at BioCells Medical, Warsaw, Poland, between 2013 and 2025. Internal clinical registry with longitudinal neurological follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
127
neuropathy patients treated since 2013
81%
measurable functional stabilisation on NRS at 3–6 months
−2.6 pts
average NRS score change at 6 months — vs. expected +0.4 pts natural progression
77%
sustained functional stability with average 3.5 years of follow-up
82%
showed improvement in one or more measured domains
78%
retained independence in basic activities of daily living (ADL) at 12 months
Motor & strength (lower-limb strength, walking endurance, fine motor coordination)
73%
Sensory & pain (burning pain, dysesthesia, tactile and temperature sensation, nocturnal neuropathic discomfort)
80%
Autonomic (balance, fall risk, distal perception)
68%
Quality of life (sleep quality, daily independence, medication reduction)
72%
2–4 weeks
Initial symptomatic relief
2–4 months
Clinically meaningful change
2–3 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on neuropathy subtype, duration and severity of nerve damage, and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Three years of constant burning in my feet. I couldn’t sleep through a single night. After treatment, the pain went from an eight to maybe a three. I walk properly again. My endocrinologist in Milan said he honestly didn’t expect the improvement he measured.”
Patient
Diabetic Peripheral Neuropathy · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Peripheral neuropathy involves nerve damage, chronic inflammation and impaired regeneration. Our protocol addresses all three simultaneously. Each programme is constructed individually after a detailed evaluation of the patient’s neuropathy subtype, nerve damage profile and symptom pattern.
Goes beyond pain management
Standard neuropathy treatment masks pain without repairing nerves. Our protocol targets nerve regeneration, inflammation and vascular repair at the biological level.
Effective across multiple neuropathy subtypes
Diabetic, autoimmune, CIPN, CIDP, idiopathic and small fiber neuropathy all respond to targeted cellular and immunomodulatory intervention.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection. Well-tolerated across all age groups, including patients with diabetes and post-cancer status.
Compatible with existing pain medication
Patients do not need to discontinue gabapentin, pregabalin or other neuropathic pain medication. Our programme integrates with your existing pain management plan.
Particularly effective in diabetic neuropathy
DPN involves both inflammatory nerve damage and vascular insufficiency. MSC therapy addresses both mechanisms simultaneously — nerve regeneration and revascularisation.
Supports actual nerve fibre repair
Unlike symptomatic medication, our protocol supports Schwann cell function and axonal regeneration — the biological processes needed for real sensory and motor recovery.
What It Is
MSCs are multipotent regenerative cells with well-documented immunomodulatory and neuroprotective properties. In peripheral neuropathy, they serve a dual role: suppressing the chronic inflammation that damages nerve tissue and supporting the biological conditions necessary for axonal and myelin regeneration.
How It Is Done
Cells are collected from the patient’s own bone marrow (autologous) or sourced from a certified donor (allogeneic), depending on clinical indications. In diabetic neuropathy, targeted local delivery may be used alongside systemic infusion to maximise nerve regeneration in the most affected areas. All cells are processed in our certified Warsaw laboratory.
Biological Mechanisms
How This Helps in Peripheral Neuropathy
In diabetic neuropathy, chronic hyperglycaemia causes both direct nerve damage and vascular insufficiency that starves nerves of oxygen and nutrients. MSCs address both mechanisms — reducing inflammation, promoting new blood vessel formation around nerve tissue and supporting the conditions needed for actual nerve fibre regeneration rather than just pain suppression.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific neuropathy subtype, nerve damage profile and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess neuropathy type, nerve conduction studies, pain pattern and functional limitations. This consultation is free and carries no obligation.
A detailed review of all medical documentation. Our medical board evaluates eligibility and designs a personalised protocol for your specific neuropathy subtype and nerve damage profile.
Cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion and/or targeted local delivery — no surgery, no general anaesthesia.
Motor and sensory rehabilitation, balance training and fall prevention exercises. Adapted to your neuropathy subtype and current functional capacity.
Your dedicated coordinator monitors nerve function, tracks pain levels, provides clinical guidance and adjusts recommendations. Repeat nerve conduction testing where appropriate to document functional change.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
The programme is well-tolerated across neuropathy subtypes, including in patients with diabetes, post-cancer status, immune compromise or advanced age. Mild transient reactions — brief fatigue or injection-site sensitivity — may occur and typically resolve within 24–48 hours.
All eligibility is confirmed individually by our physician team before treatment. A final medical assessment is performed on-site before each session.
For patients with diabetic neuropathy, blood glucose management is reviewed as part of the treatment planning process. Glycaemic control influences treatment outcomes and is discussed with each patient.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
sensory and motor recovery programme adapted to your neuropathy subtype
Balance and fall prevention training
particularly relevant in lower limb neuropathy
Medical-grade wearable monitoring
tracking activity, sleep and pain patterns
Long-term coordinator support
pain reassessment, nerve function tracking and clinical guidance
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Peripheral nerve regeneration is a gradual biological process. The period following treatment is when nerve repair consolidates into measurable functional improvement. Consistent monitoring allows us to track progress, adjust recommendations and respond to evolving clinical needs.
Get Started
Our medical team is available for a free consultation based on your neuropathy type, current symptoms and nerve conduction data. We work with all peripheral neuropathy subtypes — diabetic, autoimmune, CIPN, CIDP and idiopathic.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
